Annual report pursuant to Section 13 and 15(d)

Significant Transactions (Narrative) (Details)

v3.22.2.2
Significant Transactions (Narrative) (Details) - USD ($)
 12 Months Ended
Mar. 16, 2022
Nov. 01, 2021
Aug. 23, 2021
Jun. 30, 2022
Sep. 30, 2021
Amortization of deferred financing costs       $ 107,000  
Impairment of investment in equity security       1,760,000  
College Station Investors LLC And Bryan Capital [Member]          
Total purchase price   $ 28,750,000      
Cash payment   28,000,000      
Fair market value of property   $ 151,450      
Percentage of base rent   6.50%      
Cash consideration for equity interest acquired   $ 50,000      
Number of warrants issued   51,583      
Warrants, exercise price per share   $ 33.25      
Shares issued under the Warrant   11,583      
Fair value of the warrant   $ 217,255      
College Station Investors LLC And Bryan Capital [Member] | Secured Term Loan          
Secured term loan   $ 22,375,000      
Interest rate (as percent)   3.25%      
Unrestricted cash   $ 10,000,000      
Irrevocable letter of credit   5,469,000      
Cost incurred to attain debt   $ 214,000      
Interest expense       489,000  
Amortization of deferred financing costs       107,000  
College Station Investors LLC And Bryan Capital [Member] | IBio CMO Preferred Tracking Stock          
Warrants issuable   1      
Percentage of equity interest   0.01%      
Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]          
Collaboration and license agreement, notice duration to terminate contract     30 days    
Collaboration and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]          
Collaboration and license agreement, royalty payment term     10 years    
Collaboration and license agreement, period to cure breach of contract     60 days    
Collaboration and license agreement, notice duration to terminate contract     90 days    
Collaboration and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Event of Non-Payment [Member] | RubrYc Theraputics, Inc. [Member]          
Collaboration and license agreement, period to cure breach of contract     30 days    
Collaboration and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Clinical Development and Regulatory Milestone Payments [Member] | RubrYc Theraputics, Inc. [Member]          
Milestone payments     $ 15,000,000    
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]          
Collaboration and license agreement, period to cure breach of contract     60 days    
Collaboration and license agreement, notice duration to terminate contract     90 days    
Collaboration and license agreement, agreement term     5 years    
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Event of Non-Payment [Member] | RubrYc Theraputics, Inc. [Member]          
Collaboration and license agreement, period to cure breach of contract     30 days    
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Financing Requirement not Met [Member] | RubrYc Theraputics, Inc. [Member]          
Collaboration and license agreement, notice duration to terminate contract     30 days    
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Clinical Development and Regulatory Milestone Payments [Member] | RubrYc Theraputics, Inc. [Member]          
Milestone payments     $ 15,000,000    
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | No Biosimilar Product has been Approved [Member] | RubrYc Theraputics, Inc. [Member]          
Collaboration and license agreement, royalty payment term     10 years    
Series A-2 Preferred Stock [Member] | Stock Purchase Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]          
Stock purchase agreement, number of shares purchased 954,782   1,909,563    
Stock purchase agreement, value of shares purchased $ 2,500,000   $ 5,000,000    
Stock purchase agreement, number of shares to be purchased     954,782    
Stock purchase agreement, value of shares to be purchased     $ 2,500,000    
Preferential dividend rate percentage     8.00%    
Minimum required shares to be eligible for preferential dividend rate     1,500,000    
Proceeds from conversion of preferred stock to common stock     $ 30,000,000    
Liability for the assumed acquisition         $ 2,500,000
Impairment of investment in equity security       1,760,000  
Impairment of current prepaid expense       288,000  
Impairment of non-current prepaid expense       $ 864,000